Objective: Some patients with intact abdominal aortic aneurysm (iAAA) have consumption coagulopathy without definitive diagnosis of disseminated intravascular coagulation (DIC). The objective of this study was to reveal the clinical significance of such marginal coagulopathy (namely, pre-DIC) associated with iAAA.
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Early and Late Costs of Endovascular Abdominal Aortic Aneurysm Repair From the Endurant Stent Graft System Post Approval Study (ENGAGE PAS)
Objective: Endovascular aneurysm repair (EVAR) has become the standard of care for treatment of abdominal aortic aneurysms. Whereas the costs of EVAR during the index admission were shown with early randomized trials, these studies evaluated costs with early devices and had nothing to disclose regarding follow-up costs. Therefore, we present the early and late costs of EVAR from the Endurant Stent Graft System Post Approval Study (ENGAGE PAS).
Methods: From August 2011 to June 2012, there were 178 patients enrolled in ENGAGE PAS and treated with the Medtronic Endurant stent graft system (Medtronic, Santa Rosa, Calif) . Cost data for the index and follow-up hospitalizations were tabulated directly from hospital bills and categorized by Uniform Billing (UB-04) codes. Surgeon costs were calculated by Current Procedural Terminology codes for each intervention, and these codes were also used to impute annual imaging and clinic follow-up costs.
Results: A total of 178 patients underwent EVAR with the Endurant graft, and 171 consented for inclusion in the economic analysis. The mean total hospital cost per person for the index EVAR was $38,355, with a range from $4972 to $686,928 (Table) . Cost of the EVAR device accounted for 52% of the total cost at a mean of $20,000 per person. Annual follow-up imaging costs averaged $693, whereas annual office visits averaged $99, for a total routine follow-up cost of $792 per year. During a median follow-up of 37 months, 12 patients (7.0%) underwent 16 reinterventions. The mean cost associated with reintervention was $35,011 per person.
Conclusions: Costs associated with EVAR are driven primarily by the cost of the device. Late reintervention is uncommon, but when it occurs, it is associated with costs similar to those of the index procedure. These data will serve as a baseline for comparison with open repair and other devices. Objective: Reporting standards in clinical research allow accurate comparison between outcomes for different clinical trials. We sought to assess the proportion of published studies evaluating outcomes for elective infrarenal endovascular aneurysm repairs (EVARs) that adhered to the current Society for Vascular Surgery (SVS) reporting guidelines.
Methods: We searched PubMed indexed randomized clinical trials (RCTs) and multicenter cohort studies (MCSs) between January 1, 2010, and December 1, 2017. We identified and reviewed studies that reported clinical outcomes for infrarenal abdominal aortic aneurysm undergoing elective EVAR. We evaluated whether the following outcomes were reported at all: aneurysm rupture, aneurysm-related death, primary and secondary technical success, clinical success or clinical failure, and longitudinal outcomes; we then evaluated whether these outcomes were reported according to the current SVS reporting guidelines for EVAR (Chaikof et al, 2002) .
Results: Thirty studies that investigated infrarenal EVAR outcomes were included in our analysis: 7 RCTs and 23 MCSs. Of the 30 studies, Objective: In recent years, there has been more interest in frailty in the surgical patient and its implication for outcomes. A simplified form of the original frailty index from the Canadian Study of Health and Aging has been established as the modified frailty index (mFI) and has been used as a predictor of morbidity and mortality after surgery. In our study, we have sought to apply the mFI to open surgical repair of a ruptured abdominal aortic aneurysm.
Methods: The 2010 American College of Surgeons National Surgical Quality Improvement Program database was used; patients undergoing open surgical repair of a ruptured abdominal aortic aneurysm were identified. We applied an mFI with 11 variables based on the Canadian Study of Health and Aging frailty index to the National Surgical Quality Improvement Program comorbidities. A bivariate analysis was done using logistic regression analysis. Factors associated with increased risk of mortality were identified.
Results: A total of 258 patients (79% male, 21% female; mean age, 72.9 years; mean body mass index, 27.8; 91.8% white, 7.3% African American, 0.5% Asian, 0.5% Native Hawaiian or Pacific Islander) underwent an open surgical repair of a ruptured abdominal aortic aneurysm. Incidence of 30-day mortality was 29% (for mFI <0.27) vs 46% (for mFI 0.27); postoperative myocardial infarct, 9% (for mFI <0.27) vs 8% (for mFI 0.27); stroke, 1.6% (for mFI <0.27) vs 4.8% (for mFI 0.27); postoperative progressive renal failure, 1.6% (for mFI <0.27) vs 4.8% (for mFI 0.27); and postoperative return to the operating room, 15.8% (for mFI <0.27) vs 15.9% (for mFI 0.27).
Conclusions: This study demonstrates that the mFI can be used as a valuable tool to identify patients at a higher risk for postoperative morbidity and mortality after open surgical repair of a ruptured abdominal aortic aneurysm. The study has also shown that for an mFI of 0.27, the risk of mortality and complications increases significantly. The mFI can be used as a screening tool to identify patients who are at a high risk for development of complications.
Author Disclosures: T. Z. Ali: Nothing to disclose; F. Aziz: Nothing to disclose; E. Lehman: Nothing to disclose. Objective: Repair of aortic disease extending proximal to the left subclavian artery is challenging with few durable options. With the advent of new endovascular devices to treat aortic arch conditions, a historical comparison is required for evaluation of efficacy and safety.
Methods: A review was conducted of 19 consecutive descending aortic repairs with thoracic endovascular aortic repair (TEVAR) and left common carotid artery chimney grafts at a single institution between January 1,2011, and September 30, 2016.
Results: Indication for repair included chronic aneurysm in seven (37%), aneurysmal degeneration after type B dissection in six (31.5%), transection related to blunt trauma in two (10.5%), mycotic aneurysm in one (5%), anastomotic pseudoaneurysm with aortobronchial fistula in one (5%), pseudoaneurysm in the setting of radiation for cancer in one (5%), and large penetrating atherosclerotic ulcer in one (5%). Ten (52.6%) of the repairs were done electively. Nine (47.4%) were done urgently in the setting of chest pain (four), rupture (two), transection (two), and hemoptysis (one). Zone 2 disease was present in 79%; the remainder (21%) had zone 3 disease. All patients except one had left carotid sheath access before TEVAR deployment, which was performed as a rescue for an inadvertently covered left carotid. Subclavian or axillary revascularization was performed in all patients except those with trauma. Immediate technical success was observed in all patients. Two (10.5%) suffered right hemispheric strokes but recovered completely. There was one in-hospital death (5%) due to ruptured aneurysm in the setting of chronic type B dissection. Median length of stay was 9 days. Thirteen (68%) were discharged to home. Median follow-up was 738 days. The 2-year survival MCS, Multicenter cohort study; RCT, randomized clinical trial.
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